
Antimicrobial Resistance Initiative Third Global Patient Safety Challenge



World Health Organization






Global Antibiotic Resistance Partnership – Kenya KEMRI - RFF Nairobi, 6-7 August 2009



Patient Safety is a "Special WHO Programme" following WHA Resolution 55.18

Coordination, dissemination and acceleration of improvements in patient safety worldwide









SIGN IN PATIENT HAS CONFIRMED IDENTITY

PROCEDURI

CONSENT

SITE

CONFIRM ALL TEAM MEMBERS HAVE ROLE

TIME OUT

SURGEON, ANAESTHESIA PROFESSIONAL AND NURSE VERBALLY CONFIRM PATIENT SITE PROCEDURE

ANTICIPATED CRITICAL EVENTS

SURGEON REVIEWS: WHAT ARE THE CRITICAL OR UNEXPECTED STEPS, OPERATIVE DURATION, ANTICIPATED BLOOD LOSS?

HAS ANTIBIOTIC PROPHYLAXIS BEEN GIVEN WITHIN THE LAST 60 MINUTES?

IS ESSENTIAL IMAGING DISPLAYED?

- ANAESTHESIA TEAM REVIEWS: ARE THERE ANY PATIENT-SPECIFIC CONCERNS?
- NURSING TEAM REVIEWS: HAS STERILITY (INCLUDING INDICATOR RESULTS) BEEN CONFIRMED? ARE THERE EQUIPMENT ISSUES OR ANY CONCERNS?

NOT APPLICABLE

YES NOT APPLICABLE

YES \square

 \square

- ML/KG IN CHILDREN)?
- ES, AND ADEQUATE INTRAVENOUS ACCESS ND FLUIDS PLANNED

THAT INSTRUMENT, SPONGE AND NEEDLE COUNTS ARE CORRECT (OR NOT APPLICABLE) HOW THE SPECIMEN IS LABELLED

SIGN OUT


- (INCLUDING PATIENT NAME)
- WHETHER THERE ARE ANY EQUIPMENT PROBLEMS TO BE ADDRESSED

NURSE VERBALLY CONFIRMS WITH THE TEAM:

THE NAME OF THE PROCEDURE RECORDED

SURGEON, ANAESTHESIA PROFESSIONAL AND NURSE REVIEW THE KEY CONCERNS FOR RECOVERY AND MANAGEMENT OF THIS PATIENT

		Constant
		SITE MARKED/NOT APPLICABLE
the first		ANAESTHESIA SAFETY CHECK COMPLETED
		PULSE OXIMETER ON PATIENT AND FUNCTIONING
		DOES PATIENT HAVE A:
		KNOWN ALLERGY?
ALL ALL ALL		NO YES
		DIFFICULT AIRWAY/ASPIRATION RISK?
NECTOR N		NO YES, AND EQUIPMENT/ASSISTANCE AVAILABLE
A REAL PROPERTY AND A REAL		RISK OF >500ML BLOOD LOSS
		(7ML/KG IN CHILDREN)? NO
		YES, AND ADEQUATE INTRAVENOUS ACCESS AND FLUIDS PLANNED
		AND TEORDS FEATINED
	LAL.	



Antibiotic use: indiscriminate use in plants, fish and animals

Overuse of antibiotics in the US Washington Post, 2005

More than half of the antibiotics used in the United States are estimated to be used in animal feed for poultry, hogs, and cattle In 80 percent of cases, the drugs are used to fatten the animals faster.


Between 40,000 and 50,000 pounds of tetracycline and streptomycin - both used to treat infections in humans - are sprayed to control bacterial disease among fruit trees.

In the United States nearly 150 pounds of antibiotic are applied per acre of salmon






Antibiotic use: outpatient penicillin usage correlated with penicillin resistance, Europe 2005








Discovery of antibiotics: a faltering pipeline



Preserving effectiveness of antimicrobial therapy: globally



Launched 9/11-2001






Patient Safety Programme Progression in 2 Stages

Stage 1 (Foundation) ongoing


- Defining five topic areas and convening five working groups
- Develop Global AMR work plan based on 2001 Global Strategy
- Focus on Antibiotic Resistance
- Develop rough estimation of Global burden of resistance
- Initiate planning for global surveillance network







Input from different disease groups








Surveillance

- AMR surveillance infrastructure and informatics for resource-limited areas
 - e.g. improving laboratory & information management capacity
- Ongoing surveillance of antimicrobial use in hospitals, primary healthcare and community
- Lab network building (e.g. WHOnet users, IANPHI, EARSS)





Time trends in resistance: effects of drug usage



 β -lactamase producing *M. catharrhalis* in Finland, from Austin et al PNAS 1999





Appropriate use of AB in animals, fish and plants

- Control of veterinary drug use
- Integrated surveillance in people & animal (e.g. AGISAR)
- Critical antibiotics for human health restricted in animal production
- Antibiotics not used as growth promoters





Infection prevention

- Country situation analysis leading to specific goals
- Infection Control capacity & infrastructure building
 - Prioritizing the control of specific alert organisms
- Adopting 1st and 2nd PS Challenges principles
 - Hand Hygiene, peri-operative AB prophylaxis





Research and Development

- Setting priorities for R&D in health technologies
 - Public financing to bring products to market, including fair return to the public
- Programme to support firms in developing countries (lower opportunity costs, better economies of scale)
 - small biotech firms, academic institutions, local capacity building
- Build open source collaboration
 - e.g. access to compound libraries, open access repositories of data and open source drug discovery; financed publicly





Rational drug use and regulation

- In-depth situation analysis in countries
- Mandated, multidisciplinary group to coordinate national activities
- Adopt regulatory measures to promote rational use at national and international levels
 - e.g. restrict access of certain antibiotics, regulation of licensing and accreditation of providers
- Easy-to-use algorithms for antibiotic stewardship
 - prescription audit, e.g. peri-operative antibiotic prophylaxis, duration of antibiotic treatment, improved diagnosis





Burden of AMR


- Immediate: rough estimation of the current burden of mortality, morbidity, and cost caused by resistant pathogens
- Longer term: building of refined burden estimation methodology & disease modelling



Imperial College London



Time trends in resistance: effects of drug usage




Penicillin resistant S. pneumoniae in Iceland, from Austin et al PNAS 1999





MRSA: All-Cause Mortality





Patient Safety Programme Progression in 2 stages

Stage 2

- Global launch 2010
- Develop 3rd Challenge intervention (package)
 - Focus on antibiotic resistance
- Develop robust methodology for Burden of AMR estimation & modelling
- Develop surveillance network







Thank you http://www.who.int/patientsafety